Glutathione ester but not glutathione protects against cisplatin-induced ototoxicity in a rat model

Journal of the American Academy of Audiology

Volumn 14, Issue 3, 2003, Pages 124-133

  Campbell, Kathleen C M ^a   Larsen, Deb L ^a   Meech, Robert P ^a   Rybak, Leonard P ^a   Hughes, Larry F ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; Glutathione; Glutathione ester hearing loss; Ototoxicity; Outer hair cells

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DODECYL GALLATE; DRUG DERIVATIVE; GALLIC ACID; GLUTATHIONE; S ETHYL GLUTATHIONE; S-ETHYL GLUTATHIONE;

ANIMAL; ARTICLE; AUDITORY STIMULATION; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG DETOXIFICATION; DRUG EFFECT; EVOKED BRAIN STEM AUDITORY RESPONSE; HAIR CELL; HEARING LOSS; INTRAPERITONEAL DRUG ADMINISTRATION; RAT; ULTRASTRUCTURE;

ACOUSTIC STIMULATION; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE MODELS, ANIMAL; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; GALLIC ACID; GLUTATHIONE; HAIR CELLS, OUTER; HEARING LOSS; INJECTIONS, INTRAPERITONEAL; METABOLIC DETOXICATION, DRUG; RATS;

EID: 0141687445     PISSN: 10500545     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Anderson ME, Naganuma A, Meister A. (1990). Protection against cisplatin toxicity by administration of glutathione ester. FASEB Journal 4:3251-3255.
2. Anniko M, Sobin A. (1986). Cisplatin: Evaluation of its ototoxic potential. Am. J. Otol. 7:276-293.
3. Babu E, Gopalakrishnan VK, Navis Paul Sriganth 1., Gopalakrishnan R. Sakthisekaran D. (1995). Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester. Molecular and Cellular Biochemistry 144:7-11.
4. Boogaard PJ, Slikkerveer A, Nagelkerke JF, Mulder GJ. (1991). The role of metallothionein in the reduction of cisplatin-induced nephrotoxicity by Bi3+-pretreatment in the rat in vivo and in vitro. Biochemical Pharmacology 41(3):369-375.
5. Campbell KCM, Rybak LP, Meech RP, Hughes LF. (1996). D-Methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear. Res. 102:90-98.
6. Campbell KCM, Meech RP, Rybak LP, Hughes LF. (1999). D-methionine protects against cisplatin damage to the stria vascularis. Hear. Res. 138:13-28.
7. Church MW, Kaltenbach JA, Blakely BW, Burgio DL. (1995). The comparative effects of sodium thiosulfate, diethylcarbamate, fosfomycin, and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res. 86(1,2):195-203.
8. Di Re F., Bohm S, Oriana S, Spatti GB, Zunino F. (1990). Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother. Pharmacal. 25:355-360.
9. Estrem SA, Babin RW, Ryu JH, Moore KC. (1981). Cis-Diamminedichloroplatinum(II) ototoxicity in the guinea pig. Otolaryngol. Head Neck Surg. 89:638-745.
10. Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C. Colell A. (1998) Mitochondrial glutathione: Importance and transport. Seminars in Liver Disease, 18(4)389-401.
11. Fleischman RW, Stadnick, SW, Ethier MF, Schaeppi, U. (1975). Ototoxicity of cis-dichlorodiammine platinum (II) in the guinea pig. Toxicol Appl Pharmacol. 33:320-332.
12. Ford MS, Nie Z, Whitworth C, Rybak LP, Ramkumar V (1997). Up-regulation of adenosine receptors in the cochlea by cisplatin. Hear. Res. 111(1-2):143-52
13. Gandara DR, Perez EA, Phillips WA, Lawrence HJ, DeGregoria M. (1989). Evaluation of cisplatin dose intensity: Current status and future prospects. Anticancer Res 9:1121-1128
14. Ghibelli L, Fanelli C, Rotilio G, Lafavia E, Coppola S, Colussi C, Civitareale P, Ciriolo MR. (1998) Rescue of cells from apoptosis by inhibition of active GSH extrusion. FASEB Journal 12(6):479-86).
15. Hannemann J, Baumann K. (1988). Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: Different effects of antioxidants and radical scavengers. Toxicology 51:119-132.
16. Jones MM, Basinger MA. (1989). Thiol and thioether suppression of cis-platinum-induced nephrotoxicity in rats bearing the walker 256 carcinosarcoma. Anticancer Research 9:1937-1942.
17. Jones MM, Basinger MA, Holscher MA. (1991a). Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity. Toxicology 68:227-247.
18. Jones MM, Basinger MA, Holscher MA. (1991b). Thioether suppression of cisplatin nephrotoxicity in the rat. Anticancer Research 11:449-454.
19. Jones MM, Basinger MA Holscher MA. (1992). Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds. Fundam Appl Toxicol 18:181-188.
20. Kaern J, Trope C, Sundfoer K, Kristensen GB. (1996). Cisplatin/ 5-fluorouracil treatment of recurrent cervical carcinoma: A phase II study with long-term follow-up. Gynecologic Oncology. 60(3):387-92.
21. Kameyama Y, Gemba M. (1991a). Cisplatin-induced injury to calcium uptake by mitochondria in glutathione-depleted slices of rat kidney cortex. Japanese Journal of Pharmacology 55:174-176.
22. Komune S. (1981). Potentiating effects of cisplatin and ethacrynic acid in ototoxicity. Archives of Otolaryngology. 101:66-74.
23. Kopke RD, Liu W, Gabaizeadeh R, Jacono A, Feghali J, Spray D, Garcia P, Steinman H, Malgrange B, Ruben R, Rybak L Van De Water T. (1997). Use of organotypic cultures of corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am. J. Otol. 18:559-571.
24. Lauterman, J, Song B, McLaren J, Schacht J. (1995). Diet is a risk factor in cisplatin ototoxicity. Hear. Res. 88(1-2):47-53.
25. Leone R, Fracasso ME, Soresi E, Gimino G, Tedeschi M, Castoldi D, Monzani V, Colombi L, Usari T, Bernareggi A. (1992). Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin. Cancer Chemotherapyand Pharmacology 29:385-390.
26. Litterst CL, Bertolero F, Uozumi J. (1986). The role of glutathione and metallothionein in the toxicity and subcellular binding of cisplatin. In: McBrien DCH and Slater TF, eds. Biochemical Mechanisms of Platinum Antitumour Drugs. Oxford, England: IRL Press, 227-254.
27. Litterst CL, Tong S, Hirokata Y, Siddik ZH (1982). Alterations in hepatic and renal levels of glutathione and activities of glutathione s-transferases from rats treated with cis-dichlorodiammineplatinum-II. Cancer Chemotherapy and Pharmacology 8:57-71.
28. Lu S. (1998). Regulation of hepatic glutathione synthesis. Sem in Liver Dis 18:331-334.
29. Meech R, Campbell KCM, Hughes LF Rybak LP. (1998). A semiquantitative analysis of the effects of cisplatin on the rat stria vascularis. Hear. Res. 124:44-59.
30. Meister A. (1983). Selective modification of glutathione metabolism. Science 220:472-477.
31. Meister A. (1988). Glutathione metabolism and its selective modification. The Journal of Biological Chemistry 263(33):17205-17208.
32. Meister A, Anderson ME. (1983).Glutathione. Annual Review of Biochemistry 52:711-760.
33. Mistry P, Spargo DJ, Riley PA, McBrien DCH. (1988). The Effect of Cisplatin Upon Protein Thiol Concentration in Proximal Tubular Cells of the Rat Kidney. In: Hacker MP, Lazo JS and Tritton TR, eds. Organ Directed Toxicities of Anticancer Drugs, Martinus Nijhoff Publishing, Boston; 236.
34. Muller M. (1991). Developmental changes of frequency respresentation in the rat cochlea. Hear. Res. 56:1-7.
35. Nakano S, Gemba M. (1989). Potentiation of cisplatin-induced lipid peroxidation in kidney cortical slices by butathione depletion. Japanese Journal of Pharmacology 50:87-92.
36. Piel IJ, Meyer D, Perlia CP, Wolfe VI. (1974). Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemotherapy Reports Part I.58(6):871-875.
37. Ravi R, Rybak LP, Somani SM. (1991). Relationship of pharmacodynamic effects of cisplatin to the glutathione levels in cochlea, inferion colliculus and kidney. Pharmacologist 33(3):217.
38. Ravi R, Somani S Rybak L. (1995). Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacology and Toxicology 76: 386-394.
39. Reed DJ. (1990). Glutathione: Toxicological implications. Annual Review of Pharmacology Toxicology 30:603-631.
40. Ross D. (1988). Glutathione, free radicals and chemotherapeutic agents. Pharmacology Therapy 37:231-249.
41. Rubin JS, Wadler S, Beitler JJ, Haines H, Rosenblit A, McGill F, Goldberg G, Runowicz C. (1995). Audiologic findings in a Phase I protocol investigating the effect of WR 2721, high dose cisplatin and radiation therapy in patients with locally advanced cervical cancer. Journal of Laryngology and Otology 109(8):744-747.
42. Rybak LP, Ravi R, Somani S. (1995). Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: Antioxidant system. Fundam Appl Toxicol. 26:293-300.
43. Satoh M, Naganuma A, Imura N. (1987). Deficiency of selenium intake enhances manifestation of renal toxicity of cis-diamminedichloroplatinum in mice. Toxicology Letters 38:155-160.
44. Schucknencht H. (1993). Disorders of Intoxication: Pathology of the Ear. Philadelphia: Lea and Febiger
45. Schweitzer VG. (1993a). Cisplatin-induced ototoxicity: The effect of pigmentation and inhibitory agents. Laryngoscope 103:1-52.
46. Schweitzer VG. (1993b). Ototoxicity of chemotherapeutic agents. The Otolaryngologic Clinics of North America 26(5):759-789
47. Schweitzer VG, Dolan DF, Davidson T, Abrams, GE, Snyder R. (1986). Cisplatin amelioration of ototoxicity by fosfomycin. Laryngoscope 96:948-958.
48. Shapiro JD, Rothenberg ML, Sarosy GA, Steinberg SM, Adamo DO, Reed E, Ozols RF, Kohn EC. (1998). Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial cancer. Cancer. 83(9):1980-8.
49. Sugihara K, Nakano S, Gemba M. (1987a). Effect of cisplatin on in vitro production of lipid peroxides in rat kidney cortex. Japanese Journal of Pharmacology 44:71-76.
50. Sugihara K, Nakano S, Koda M, Tanaka K, Fukuishi N, Gemba M. (1987b). Stimulatory effect of cisplatin on production of lipid peroxidation in renal tissues. Japanese Journal of Pharmacology 43:247-252.
51. Tedeschi M., Bohm S, Di Re F, Oriana S, Spatti GB, Tognella S, Zunino F. (1990). Glutathione and detoxification. Cancer Treatment Reviews 17:203-208.
52. Vermorken JB, Kapteijn TS, Hart AAM, Pinedo HM. (1983). Ototoxicity of cis- diamminedichloroplatinum(II): Influence of dose, schedule and mode of administration. European Journal of Cancer & Clinical Oncology. 19(1):53-58.
53. Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, Tofanetti O. (1989). Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chemical-Biological Interactions 70:89-101.
54. Zunino F, Tofanetti 0, Besati, A, Cavalletti E, Savi G. (1983). Protective effect of reduced glutathione against cis-dichlorodiammine platinum(II)-induced nephrotoxicity and lethal toxicity. Tumori 69:105-111.